Participation in the "Pharmaceutical Visionary Conference 2024
Aiming for Dialogue and Co-creation among Diverse Stakeholders
November 27, 2024
- The Japan Pharmaceutical Manufacturers Association (JPMA) is pleased to announce its participation in the "Pharmaceutical Visionary Conference 2024 (hereafter referred to as "the Conference")" organized by seven groups and organizations* including patient groups and governments.
The conference was conceived at the initiative of the National Federation of Cancer Patients' Organizations, and was planned to work with a greater number of stakeholders** to resolve issues related to healthcare and pharmaceuticals, and to promote patient participation initiatives, in order to have a greater impact and influence on the world.
This year's meeting, titled "Aiming to Improve Access to Medicines," was held on November 1, 2024. During the meeting, participants exchanged opinions on current activities and issues related to the two themes of (1) patient participation in drug research and development and (2) how information should be provided.
At the end of the meeting, it was confirmed that this meeting would not be a one-time event and that each stakeholder should play their own role and cooperate and collaborate with each other, and the following "Joint Message" was compiled.
Joint Message
<Outline of the Agenda
1) Patient Participation in Drug Research and Development
- There are different levels of understanding and efforts for patient involvement among stakeholders, and there are issues specific to each disease and therapeutic area, as well as issues unique to each stakeholder.
- In order to resolve these issues and promote patient engagement, it is necessary to promote dialogue, information sharing, and mutual understanding across stakeholder boundaries, and to improve the literacy of each stakeholder.
-
Patient involvement" has just begun, but in the future, we will aim to address "citizen involvement" as well.
- In an age when anyone can transmit and obtain information via SNS, etc., there is a need to create an environment in which appropriate information is delivered to medical professionals and patients at the right time.
- Information on stable supply and safety, as well as information on clinical trials (clinical studies), can be said to be life-threatening information for patients.
Through co-creation with each stakeholder gathered at this conference, the Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue its efforts to resolve issues related to medicines and treatments needed by patients and their families, and to realize a society that is easier to live in.
* Seven groups/organizations (in no particular order): National Federation of Cancer Patients' Associations, Japan Intractable Diseases Society, Hidamari Tanpopo (Association of Families Affected by Organic Acid and Fatty Acid Metabolism Disorders), ASrid (non-profit organization), Ministry of Health, Labor and Welfare, Pharmaceuticals and Medical Devices Agency, and Pharmaceutical Manufacturers Association of Japan **
＜Reference: Event Summary
Date: Friday, November 1, 2024 1:15 p.m. - 3:15 p.m.
Participants] (in alphabetical order)
Shinsuke Amano (President, National Federation of Cancer Patients' Associations)
Reference
Participation in "Pharmaceutical Visionary Conference 2024" (English version)
For inquiries, please contact
Public Relations Department, Japan Pharmaceutical Manufacturers Association
- Phone: +81-3-3241-0374
- 03-3241-0374